Explore News
-
Mounjaro, Zepbound Cut Heart Disease Death Risk by 22%
New clinical trial data shows GLP-1 medications Mounjaro and Zepbound significantly reduce the risk of…
-
Scientists say 8,500 steps a day could stop weight from creeping back
New study reveals daily step goal for weight loss maintenance
-
Why 8,500 Steps a Day Matters for Dieters
Research finds daily step goal helps with weight maintenance
-
Semaglutide Shows Promising Efficacy in Older Adults Aged Over 65 Years
New analysis of STEP trials demonstrates safety and efficacy
-
45% of Adults Dine Out Weekly—Fueling Obesity Surge
A major analysis of dietary habits across 63 countries shows that frequent eating out is…
-
New Obesity Discovery Rewrites Decades of Fat Science
Scientists uncover a surprising secret inside fat cells
-
58% of Parents Pestered for Junk Food by Children, Survey Reveals
A nationally representative study of parents in England finds persistent child-led demands for high-fat, salt,…
-
New Drug Cuts Weight by 30% in Early Trials
A pioneering ‘Trojan horse’ drug uses dual hormone signals to deliver metabolic boosters directly into…
-
Next-Gen GLP-1 Drug Survodutide Shows 16% More Weight Loss Than Zepbound
A phase 3 trial reveals survodutide, a dual GLP-1 and glucagon receptor agonist, led to…
-
New GLP-1 Drug Shows Promise for Weight Loss
A new weight loss drug has shown promising results in a phase 3 clinical trial
